Caisson Interventional

Caisson Interventional was a Minnesota-based, privately held medical device company focused on developing a novel transcatheter mitral valve replacement implant with a fully transvenous delivery system. Its TMVR technology aimed to provide a minimally invasive alternative for patients with severe symptomatic mitral regurgitation. The company's lead product was under investigation through the FDA's Early Feasibility Study program and other international sites when it was acquired by LivaNova in May 2017 for up to $72 million. The device featured unique design elements such as full retrievability before final release, enhancing procedural safety. Clinical results at the time were limited to feasibility/safety endpoints; no pivotal or commercial data available.